Evidence map›Paper›PMID 41599718›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Affinity- and Format-Dependent Pharmacokinetics of

Simon Leekens, Peter Casteels, Tom Van Bogaert, Pieter Deschaght, Veronique De Brabandere, Christopher Cawthorne, Guy Bormans, Frederik Cleeren

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Evaluation of albumin-binding PD-L1-targeted VHH for PET imaging in colorectal cancer.American journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simon LeekensLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
Peter CasteelsSanofi Ghent, 9000 Ghent, Belgium.
Tom Van BogaertSanofi Ghent, 9000 Ghent, Belgium.ORCID 0009-0001-7530-3722
Pieter DeschaghtSanofi Ghent, 9000 Ghent, Belgium.
Veronique De BrabandereSanofi Ghent, 9000 Ghent, Belgium.
Christopher CawthorneDepartment of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-5975-0354
Guy BormansLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-0335-7190
Frederik CleerenLaboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-3692-1608

Funding

Flanders Innovation and Entrepreneurship HBC.2021.0814
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DFO*half-life extensionnanobodypharmacokineticspositron emission tomography (PET)thiol–maleimide conjugation

Identifiers

PMID41599718
PMCPMC12845014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.